Replimune Group
Replimune Group is a clinical-stage biotech developing engineered HSV-1 oncolytic immunotherapies (RP1, RP2, RPx platform) for advanced melanoma and other solid tumors, with lead candidate RP1 currently under FDA BLA review (PDUFA April 10, 2026).
- Company typePublic
- Founded2015
- HeadquartersWoburn, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Replimune Group does
Replimune Group Inc. is a clinical-stage biotechnology company founded in 2015 and headquartered in Woburn, Massachusetts. The company develops a portfolio of oncolytic immunotherapies built on its proprietary RPx platform, which uses engineered herpes simplex virus type 1 (HSV-1) — incorporating transgenes such as GM-CSF, GALV-GP R-, and (for RP2) anti-CTLA-4 — to directly lyse tumor cells while inducing a systemic anti-tumor immune response capable of addressing heterogeneity that contributes to checkpoint inhibitor resistance. Its lead candidate, RP1 (vusolimogene oderparepvec), is being evaluated in combination with Bristol Myers Squibb's nivolumab for advanced melanoma; RP2 is in development for metastatic uveal melanoma and hepatocellular carcinoma (the latter in combination with Roche's atezolizumab/bevacizumab). Replimune retains full commercial rights to both assets.
The company operates an integrated model that includes a 63,000-square-foot GMP viral immunotherapy manufacturing facility in Framingham, Massachusetts, and a UK subsidiary (Replimune Ltd.) in Milton Park, Abingdon. Replimune is publicly traded on NASDAQ under the ticker REPL and has financed operations through venture rounds ($30M Series A in 2015, $55M Series B in 2017), later-stage private and public equity (~$655M across 2019-2024 including a $225M public offering in December 2022 and a $100M PIPE in June 2024), and a $200M structured debt facility from Hercules Capital (October 2022). Its intended revenue model is direct sales to oncology centers and specialty pharmacy distribution for RP1 and follow-on products, contingent on regulatory approval.
The commercial pathway has been materially disrupted: the FDA issued two Complete Response Letters rejecting RP1 in advanced melanoma, the second of which triggered a 60% workforce reduction in April 2026 and a signaled potential scale-back of U.S. manufacturing. As of December 31, 2025, Replimune held $269.1M in cash (approximately $325M pro forma following a January 2026 ATM raise and additional Hercules draw), and the FDA accepted the BLA resubmission with a PDUFA target action date of April 10, 2026 — the single most important catalyst for the company's forward trajectory.
Replimune Group firmographics
Firmographics- Name
- Replimune Group
- Legal name
- Replimune Group Inc.
- Website
- https://replimune.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Replimune Group is a clinical-stage biotech developing engineered HSV-1 oncolytic immunotherapies (RP1, RP2, RPx platform) for advanced melanoma and other solid tumors, with lead candidate RP1 currently under FDA BLA review (PDUFA April 10, 2026).
- Ownership category
- akta.pro rank
Replimune Group industry classification
Industry- Product category
- Oncology Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
Keywords
Where Replimune Group is headquartered
LocationHeadquarters
- HQ city
- Woburn
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Replimune Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical/Biologic Product Sales: Pre-commercial stage company with no approved products. Expected to generate revenue from sales of RP1 and other oncolytic immunotherapy candidates pending FDA approval. Clinical-stage biotech developing oncolytic immunotherapies for solid tumors.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Replimune Group product offering
Product offeringCore offering
Replimune is a clinical-stage biotechnology company developing a portfolio of investigational oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus type 1 (HSV-1)-based technology designed to directly destroy tumor cells and activate a systemic anti-tumor immune response. Its lead candidates, RP1 (vusolimogene oderparepvec) and RP2, are being evaluated in combination with checkpoint inhibitors (nivolumab, atezolizumab, bevacizumab) for advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma.
Product overview
Replimune Group is a clinical-stage biotech company developing a portfolio of oncolytic immunotherapies built on its proprietary RPx platform. The company's core products include RP1 (vusolimogene oderparepvec) and RP2, both engineered herpes simplex virus type 1 (HSV-1)-based oncolytic immunotherapies designed to destroy tumors locally and ignite a systemic anti-tumor immune response. RP1 is being evaluated for advanced melanoma and non-melanoma skin cancers, while RP2 is being studied for metastatic uveal melanoma and hepatocellular carcinoma. The RPx platform enables injection into both superficial and deep lesions to address tumor heterogeneity that can contribute to checkpoint inhibitor resistance.
Differentiator
Problem solved
Functional benefit
Products and services
- RP1 (vusolimogene oderparepvec) An investigational engineered HSV-1-based oncolytic immunotherapy designed to kill tumor cells locally and activate a systemic anti-tumor immune response, intended for use in combination with nivolumab in patients with advanced melanoma and non-melanoma skin cancers.
- RP2 An investigational engineered HSV-based oncolytic immunotherapy enhanced with anti-CTLA-4 expression to boost tumor killing and immune activation, being studied for metastatic uveal melanoma and hepatocellular carcinoma in combination with checkpoint inhibitors.
- RPx Platform Proprietary next-generation HSV-1-based oncolytic immunotherapy platform with a dual mechanism of action combining direct tumor cell lysis with systemic immune activation; enables injection into both superficial and deep/visceral tumors to address tumor heterogeneity contributing to checkpoint inhibitor resistance.
Quantifiable outcome
- 33.6% objective response rate in advanced melanoma patients who failed anti-PD-1 therapy (IGNYTE trial)
- +4 more outcomes
Companies that use Replimune Group
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Replimune Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Replimune Group partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Bristol Myers Squibb (BMS)coreClinical trial collaboration and supply agreement for nivolumab (Opdivo) used in combination with RP1 in IGNYTE trial. Replimune retains full commercial rights to RP1. BMS supplies nivolumab while Replimune leads development and commercialization.
- RochecoreClinical trial collaboration and supply agreement for atezolizumab and bevacizumab for use in RP2-003 trial for hepatocellular carcinoma. Replimune retains full rights to RP2.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Replimune Group competitors and assessment
Company assessmentEmerging players
- Vyriad: Vyriad is a clinical-stage company developing engineered oncolytic vesicular stomatitis virus (VSV) and measles virus platforms. Comparable as a developer of oncolytic virus immunotherapies targeting solid tumors with systemic immune activation.
- DNAtrix: DNAtrix is developing oncolytic adenovirus DNX-2401 (tasadenoturev) for glioblastoma and other solid tumors. Comparable as a clinical-stage peer using oncolytic virus approaches to drive tumor-selective killing and immune activation.
- Genelux Corporation: Genelux is developing Olvi-Vec and other oncolytic vaccinia virus immunotherapies for solid tumors including ovarian cancer and lung cancer. Comparable as a clinical-stage peer building an oncolytic virus platform with systemic immune activation.
- Turnstone Biologics: Turnstone Biologics develops oncolytic virus-based immunotherapies combined with tumor-infiltrating lymphocytes. Comparable as an emerging oncolytic immunotherapy peer focused on combining viral tumor killing with immune activation in solid tumors.
- Cold Genesys: Cold Genesys develops oncolytic adenovirus-based immunotherapies including CG0070 for bladder cancer. Comparable as a clinical-stage peer focused on engineered oncolytic virus immunotherapies for solid tumors.
- Lokon Pharma: Lokon Pharma develops LOAd700-series oncolytic adenoviruses armed with immunostimulatory transgenes. Comparable as a small clinical-stage peer building an armed oncolytic virus platform with mechanisms analogous to Replimune's RPx backbone.
Direct peers
- Iovance Biotherapeutics: Iovance developed and commercialized lifileucel (Amtagvi), the first FDA-approved TIL cell therapy for advanced melanoma. Comparable because it competes in the same post-PD-1 refractory melanoma setting that Replimune is targeting with RP1 + nivolumab.
- Oncorus: Oncorus is a clinical-stage biotech developing intravenously administered oncolytic herpes virus immunotherapies for solid tumors. Comparable as a direct competitor using HSV-based oncolytic platforms aimed at systemic anti-tumor immune activation.
Regional players
- Targovax: Targovax is a Scandinavian clinical-stage company developing oncolytic virus immunotherapies (ONCOS-102) for mesothelioma and other solid tumors. Comparable as an oncolytic virus immunotherapy peer, though operating primarily in European clinical development.
Broad incumbents
- Amgen: Amgen commercializes Imlygic (talimogene laherparepvec/T-VEC), the only FDA-approved oncolytic immunotherapy, and is a direct predecessor to Replimune via BioVex. Comparable because both target solid tumors with engineered herpes virus-based oncolytic platforms, though Amgen operates as a broad biopharma incumbent.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks2 records
Key highlights7 records
Customer concentration
Replimune Group social profiles
Digital presenceReplimune Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Replimune Group leadership team
Management profileNumber of profiles
Profiles11 records
Replimune Group subsidiaries and ownership
Company hierarchySubsidiaries1 record
Replimune Group funding detail
Funding detailFunding overview
Funding rounds11 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Replimune Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Replimune Group
What does Replimune Group do?
Replimune is a clinical-stage biotechnology company developing a portfolio of investigational oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus type 1 (HSV-1)-based technology designed to directly destroy tumor cells and activate a systemic anti-tumor immune response. Its lead candidates, RP1 (vusolimogene oderparepvec) and RP2, are being evaluated in combination with checkpoint inhibitors (nivolumab, atezolizumab, bevacizumab) for advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma.
Is Replimune Group a public or private company?
Replimune Group is a public company. It is classified as public and is currently operating.
When was Replimune Group founded?
Replimune Group was founded in 2015. It employs 251 to 500 people.
Where is Replimune Group based?
Replimune Group is headquartered in Woburn, United States, in the North America region.
How does Replimune Group make money?
One revenue line is on record: pharmaceutical/Biologic Product Sales.
Who are Replimune Group's main competitors?
Emerging players on record are Vyriad, DNAtrix, Genelux Corporation, Turnstone Biologics, Cold Genesys and Lokon Pharma. Direct peers are Iovance Biotherapeutics and Oncorus. Targovax is listed as a regional player. Amgen is listed as a broad incumbent.
Does Replimune Group have an API?
No public API is recorded for Replimune Group.
What industry is Replimune Group in?
Replimune Group's product category is Oncology Biologics. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches). Its NAICS code is 325414 and its SIC code is 2836.